Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Home CompaniesAida Pharmaceuticals Inc

Aida Pharmaceuticals Inc

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
0.0003 USD 0.00(0%)
Last update at 2026-10-27T20:00:00Z
VOLUME
2000
Market Cap
12.55M

Momentum Score

…

Aida Pharmaceuticals, Inc., together with its subsidiaries, engages in the formulation, clinical testing, registration, manufacture, sales, and marketing of pharmaceutical and genetic products in mainland China. It offers antibiotics, cardiovascular, and anti-cancer drugs. The company provides its products in the form of powder for injection; and liquid for intravenous injection, capsule, tablet, and ointment. The company provides Etimicin Sulfate, an injectable powder form, as well as rh-Apo2l, a biopharmaceutical therapy for cancers. Aida Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Hangzhou, China.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.00
High
52 Week Price Range
0.00
Low
0.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Aida Pharmaceuticals Inc is quoted on the OTC Pink market and has limited publicly available information about its operations and product pipeline. Long-term growth for a small pharmaceutical issuer typically depends on successful clinical development, regulatory approvals and commercialization or partnering, outcomes that could support shareholder value if achieved. The company may appeal to investors seeking speculative, early-stage exposure to potential drug-development upside.
Material investment risks include sparse public disclosures, low trading liquidity on the OTC Pink market, dependence on external financing and substantial clinical, regulatory and execution uncertainty.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
40.51M
Revenue Per Share
1.50
Gross Profit TTM
22.30M
Debt / Equity
2.51
ROE
-1.79%
Net Debt
24.97M
ROCE
17.54%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2007-12-31 2006-12-31 2005-12-31 2004-12-31
Type yearly yearly yearly yearly
Date 2007-12-31 2006-12-31 2005-12-31 2004-12-31
Income before tax 2.02M 2.32M 1.51M 2.53M
Minority interest 7.87M 5.18M 3.57M 1.56M
Net income 2.74M 1.45M 1.47M 1.63M
Selling general administrative 8.91M 11.08M 13.98M 7.70M
Gross profit 14.69M 15.56M 16.19M 10.82M
Ebit 4.19M 3.85M 1.63M 2.86M
Ebitda 6.06M 5.93M 3.32M -
Depreciation and amortization 1.87M 2.08M 1.69M -
Non operating income net other 0.00M 0.00M 0.00M 0.00M
Operating income 5.45M 3.94M 2.12M 2.86M
Other operating expenses 23.76M 25.71M 22.41M 0.00M
Interest expense 2.02M 1.70M 1.10M 0.00M
Extraordinary items 0.00M 0.00M 0.00M 0.00M
Non recurring 0.00M 0.00M 0.00M 0.00M
Other items 0.00M 0.00M 0.00M 0.00M
Income tax expense 0.36M 0.17M 0.14M 0.15M
Total revenue 29.20M 29.64M 24.53M 15.65M
Total operating expenses 9.25M 11.63M 14.07M 12.79M
Cost of revenue 14.51M 14.08M 8.33M 4.82M
Total other income expense net 1.26M 0.09M 0.49M -0.32M
Discontinued operations 0.00M 0.00M 0.19M 0.09M
Net income from continuing ops 4.32M 2.15M 1.36M 2.38M
Net income applicable to common shares 2.74M 1.45M 1.47M 1.63M
Preferred stock and other adjustments 0.00M 0.00M 0.00M 0.00M
Breakdown 2007-12-31 2006-12-31 2005-12-31 2004-12-31
Type yearly yearly yearly yearly
Date 2007-12-31 2006-12-31 2005-12-31 2004-12-31
Total assets 62.73M 53.81M 42.66M 25.25M
Intangible assets 9.03M 9.47M 3.54M 0.77M
Other current assets 1.03M 0.26M 2.22M 4.65M
Total liab 41.54M 38.28M 32.37M 18.58M
Total stockholder equity 13.32M 10.35M 6.72M 5.11M
Deferred long term liab 0.00M 0.00M 0.00M 0.00M
Other current liab 4.60M 3.41M 5.19M 6.68M
Common stock 0.03M 0.03M 0.15M 0.02M
Retained earnings 7.33M 4.59M 3.14M 1.67M
Other liab 1.02M 2.09M 0.39M 0.17M
Good will 0.00M 0.00M 0.00M 0.00M
Other assets 0.20M 0.46M 3.64M 1.98M
Cash 8.40M 6.12M 3.13M 2.81M
Total current liabilities 38.87M 34.38M 28.26M 17.31M
Current deferred revenue 0.14M 0.17M 0.11M -
Net debt 24.97M 23.44M 22.04M -
Short term debt 31.72M 27.63M 21.45M 0.00M
Short long term debt 1.37M 0.00M 0.00M 0.00M
Short long term debt total 33.37M 29.55M 25.17M -
Other stockholder equity 5.20M 5.20M 3.29M 0.00M
Property plant equipment 17.02M 14.01M 12.84M 3.57M
Total current assets 36.28M 28.63M 22.41M 18.28M
Long term investments 0.21M 0.30M 0.22M 0.64M
Net tangible assets 4.29M 0.78M 3.18M 4.34M
Short term investments 10.55M 0.36M 0.00M 0.00M
Net receivables 10.83M 16.68M 13.71M 7.99M
Long term debt 1.65M 5.64M 3.72M 1.09M
Inventory 3.84M 2.81M 3.35M 2.83M
Accounts payable 2.55M 3.33M 1.62M 0.85M
Total permanent equity 0.00M 0.00M 0.00M 0.00M
Noncontrolling interest in consolidated entity 0.00M 0.00M 0.00M 0.00M
Temporary equity redeemable noncontrolling interests 0.00M 0.00M 0.00M 0.00M
Accumulated other comprehensive income 0.76M 0.53M 0.14M 0.00M
Additional paid in capital 0.00M 0.00M 0.00M 0.00M
Common stock total equity 0.00M 0.00M 0.00M 0.00M
Preferred stock total equity 0.00M 0.00M 0.00M 0.00M
Retained earnings total equity 0.00M 0.00M 0.00M 0.00M
Treasury stock 0.00M 0.00M 0.00M 0.00M
Accumulated amortization 0.00M 0.00M 0.00M 0.00M
Non currrent assets other 0.21M 1.25M 3.65M 0.00M
Deferred long term asset charges 0.00M 0.00M 0.00M 0.00M
Non current assets total 26.45M 25.18M 20.25M 0.00M
Capital lease obligations 0.00M 0.00M 0.00M 0.00M
Long term debt total 0.00M 0.00M 0.00M 0.00M
Breakdown 2007-12-31 2006-12-31 2005-12-31 2004-12-31
Type yearly yearly yearly yearly
Date 2007-12-31 2006-12-31 2005-12-31 2004-12-31
Investments -8.89M -0.49M -0.56M -0.56M
Change to liabilities -0.79M 1.71M -0.92M 0.13M
Total cashflows from investing activities -11.75M -4.38M -4.78M -2.16M
Net borrowings 3.85M 4.27M 0.50M 5.80M
Total cash from financing activities 5.02M 4.45M -1.17M 4.98M
Change to operating activities 0.24M -0.66M 2.88M -3.77M
Net income 2.74M 1.45M 1.47M 1.63M
Change in cash 2.28M 2.99M 0.32M 0.29M
Begin period cash flow 6.12M 3.13M 2.81M -
End period cash flow 8.40M 6.12M 3.13M 2.81M
Total cash from operating activities 8.39M 2.66M 6.12M -2.52M
Depreciation 1.87M 2.08M 1.69M 0.61M
Other cashflows from investing activities 1.06M 1.56M -3.53M -5.39M
Dividends paid 0.00M 0.00M 0.00M 0.00M
Change to inventory -1.03M 0.54M 1.79M 0.10M
Change to account receivables 3.94M -4.64M -2.71M -2.00M
Sale purchase of stock 0.00M 0.00M 0.00M 0.00M
Other cashflows from financing activities 5.02M 4.45M -1.17M -1.79M
Change to netincome 1.55M 1.85M 1.53M 1.28M
Capital expenditures 3.61M 2.97M 0.70M 1.16M
Change receivables 0.00M 0.00M 0.00M 0.00M
Cash flows other operating 0.00M 0.00M 0.00M 0.00M
Exchange rate changes 0.00M 0.00M 0.00M 0.00M
Cash and cash equivalents changes 0.00M 0.00M 0.00M 0.00M
Change in working capital 2.14M -2.73M 2.37M -
Stock based compensation 1.58M 0.70M - -
Other non cash items 1.69M 2.36M 0.59M -
Free cash flow 4.78M -0.31M 5.42M -

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
AIDA
Aida Pharmaceuticals Inc		 -
-%		 0.00 - - 0.31 0.77 0.21 3.43
MKKGY
Merck KGaA ADR		 0.37
1.15%		 32.62 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -
-%		 158.72 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.12
0.59%		 20.15 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 -3.18
7.73%		 37.97 - 10.66 0.01 1.16 2.94 23.11

Profile*

Aida Pharmaceuticals Inc

Aida Pharmaceuticals, Inc., together with its subsidiaries, engages in the formulation, clinical testing, registration, manufacture, sales, and marketing of pharmaceutical and genetic products in mainland China. It offers antibiotics, cardiovascular, and anti-cancer drugs. The company provides its products in the form of powder for injection; and liquid for intravenous injection, capsule, tablet, and ointment. The company provides Etimicin Sulfate, an injectable powder form, as well as rh-Apo2l, a biopharmaceutical therapy for cancers. Aida Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Hangzhou, China.

31 Dingjiang Road, Hangzhou, China, 310016

86 571 8580 2712

450

Name Title Year Born
Mr. Biao Jin Chairman and Chief Exec. Officer 1948
Ms. Lin Hui Chief Financial Officer and Principal Accounting Officer 1966
Mr. Yue Jun Jiang Chief of Investment Department and Sec. 1975
Mr. Qiu Jiajun Member of Compensation Committee and Director 1966
Mr. Biao Jin Chairman and Chief Executive Officer 1948
Mr. Yue Jun Jiang Chief of Investment Department and Secretary 1975

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ROMA
USD 7.00
+49.25%
AXGN
USD 49.25
+31.47%
KIDS
USD 30.80
+29.30%
GMAB
USD 57.29
+28.25%
PRME
USD 5.36
+23.22%
BCAX
USD 9.76
-44.16%
AXG
USD 0.03
-29.00%
OTLY
USD 8.56
-27.15%
INBX
USD 73.29
-23.38%
PARA
USD 3.36
-23.29%

Equity Sectors*

  • Basic Materials

    +0.02%

  • Communication Services

    -0.63%

  • Consumer Cyclical

    -0.11%

  • Consumer Defensive

    -0.45%

  • Energy

    +0.39%

  • Financial Services

    -0.10%

  • Financials

    -0.81%

  • Healthcare

    +1.03%

  • Industrials

    +0.32%

  • Real Estate

    -0.31%

  • Technology

    +0.59%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…